Research

Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry

Our Research

Kadima Neuropsychiatry conducts clinical trials of cutting-edge, experimental novel treatments for various mental health conditions, including depression and treatment-resistant depression, generalized anxiety disorder, and PTSD. The experimental treatments that are currently, or soon to be, tested at KADIMA, for a variety of psychiatric conditions, include psilocybin, LSD, DMT, alternate form of ketamine, other medications with novel mechanisms of action, innovative medical devices, digital mental health apps, and virtual reality. If you want to learn more about the studies we’re doing, please ask! 

Research

Active Research

Beckeley

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Sponsor: Relmada Therapeutics

Investigational Treatment:  REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.

Read more about this study…

The MOOD Study – External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD).

Sponsor: Neurolief

Investigational Treatment:  Relivion®DP is a non-invasive and multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders  – Learn more about the investigational treatment

Read more about the study…

Cognitive Behavioral Therapy (CBT) in adjunct with Deep Transcranial Magnetic Stimulation (dTMS) for Major Depressive Disorder (MDD)

Sponsor: Brainsway

Investigational Treatment:  CBT-based, mobile-delivered, intervention platform. Learn more about the investigational treatment.

Read more about this study…

Long Term Follow Up Study to Psilocybin Trials, COMP 001 And COMP 003

Sponsor: Compass Pathways

Investigational Treatment:  COMP360, an oral formulation of psilocybin. Learn more about the investigational treatment.

Read more about this study…

Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Sponsor: Relmada Therapeutics

Investigational Treatment:  REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.

Read more about this study…

Learn About Kadima's Advanced Treatments for Mental Health

compassion
introspect
brainsway

Recently Completed Trials

1. Compass Pathways, COMP001
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression. Read More
2. Compass Pathways, COMP003
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression.  Read More

Get in Contact

Address: 3252 Holiday Court, Suite 112 La Jolla, CA 92037

Email: info@kadimanp.com

(858)412-4130